In these immune checkpoint analysis results, we discovered a hot immunotherapeutic molecule, cytotoxic T-lymphocyte-associated protein 4 (CTLA4), which may guide the treatment of CTLA4 antibodies such as ipilimumab in lung adenocarcinoma. This evidence concerns the gene CTLA4 and lung adenocarcinoma.